NewAmsterdam Pharma (NAMS) Treasury Shares (2022 - 2026)
NewAmsterdam Pharma (NAMS) posted Treasury Shares of $1.0 million for Q1 2026, up 38.34% sequentially from $728283.0 in Q4 2025, and up 51.78% YoY from $663790.0 in Q1 2025.
NewAmsterdam Pharma (NAMS) Treasury Shares (2022 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Treasury Shares for 5 years, with the latest figure at $1.0 million in Q1 2026.
- Quarterly Treasury Shares rose 51.78% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (up 51.78% YoY) and the FY2025 annual result came in at $728283.0, up 409.28% from the prior year.
- Treasury Shares grew to $1.0 million in Q1 2026 per NAMS's latest filing, from $728283.0 in the prior quarter.
- Over five years, Treasury Shares peaked at $1.0 million in Q1 2026 and troughed at $143002.0 in Q4 2024.
- A 5-year average of $640210.7 and a median of $621105.2 in 2022 frame the typical range for Treasury Shares.
- The sharpest annual moves came in 2024 and 2025: Treasury Shares sank 76.51% in 2024, then surged 409.28% in 2025.
- Over 5 years, Treasury Shares stood at $621105.2 in 2022, then fell by 1.98% to $608779.0 in 2023, then tumbled by 76.51% to $143002.0 in 2024, then soared by 409.28% to $728283.0 in 2025, then surged by 38.34% to $1.0 million in 2026.
- According to Business Quant data, Treasury Shares over the past three periods registered $1.0 million, $728283.0, and $724908.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - | 993,416.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 993,416.00 |
| Jun 30, 2026 | 993,416.00 |
| Mar 31, 2026 | 1.01 Mn |
| Mar 31, 2026 | 1.01 Mn |
| Dec 31, 2025 | 728,283.00 |
| Dec 31, 2025 | 728,283.00 |
| Sep 30, 2025 | 724,908.00 |
| Sep 30, 2025 | 724,908.00 |
| Jun 30, 2025 | 718,584.00 |
| Jun 30, 2025 | 718,584.00 |
| Mar 31, 2025 | 663,790.00 |
| Mar 31, 2025 | 663,790.00 |
| Dec 31, 2024 | 143,002.00 |
| Dec 31, 2024 | 143,002.00 |
| Sep 30, 2024 | 608,779.00 |
| Sep 30, 2024 | 608,779.00 |
| Jun 30, 2024 | 608,779.00 |
| Jun 30, 2024 | 608,779.00 |
| Mar 31, 2024 | 608,779.00 |
| Mar 31, 2024 | 608,779.00 |